Notice of Preliminary Results

RNS Number : 7767Z

Oxford Biomedica PLC

20 January 2011

 

OXFORD BIOMEDICA: NOTICE OF PRELIMINARY RESULTS

RESULTS DATE: 2 MARCH 2011

Oxford, UK - 20 January 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2010 on Wednesday 2 March 2011.

An analyst briefing will be held at 9:30am GMT on Wednesday 2 March 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.

Simultaneously to the analyst briefing at 9:30am GMT, there will be a live audio webcast of the presentation.  To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing.  A replay will be made available shortly after the presentation.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media/Financial Enquiries: Emma Thompson/Amber Bielecka/Rob Newman M:Communications	Tel: [phone]
US Enquiries: Simon Harnest The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

NOREAPFNFELFEFF